WaveMan
WaveMan · Company
ZLAB · Zai Lab Ltd
> Search tickers & screens ⌘K
LIVE
← All companies

ZLAB Zai Lab (ZLAB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001704292
Quote by TradingView
Form 144 · 4
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
43
13F, latest reported quarter
Conversions, 180 days
13
Codes C/M, not in net · $802.3K priced

What the filings say about ZLAB

Insiders, 180 days
-$5.1M net sold
1 buyer · 4 sellers · 7% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.8M
4 notices

Zai Lab insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Zai Lab Ltd insiders sold a net $5.1M of stock across 241 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Chen Yajing
Chief Financial Officer
SELL
2026-08-21 SECtraded 2026-08-19
260
$7.0K
-5.1%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Aug 11, 2026.
  • The trade is 0.7% of the 35,635 shares held after it.
  • 1 other insider sold within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Chen Yajing sold about $7.0K of ZLAB under a 10b5-1 plan on Aug 19, 2026; 1 other insider sold within 30 days and 43 funds added in the latest 13F quarter.
Lis William
Director
SELL
2026-08-13 SECtraded 2026-08-12
8,506
$212.7K
-6.0%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 22, 2026.
  • The trade is 20.3% of the 41,931 shares held after it.
  • 1 other insider sold within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lis William sold about $212.7K of ZLAB on Aug 12, 2026; 1 other insider sold within 30 days and 43 funds added in the latest 13F quarter.
Chen Yajing
Chief Financial Officer
SELL
2026-08-13 SECtraded 2026-08-11
619
$15.5K
-6.0%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Jun 26, 2026.
  • The trade is 1.8% of the 35,072 shares held after it.
  • 1 other insider sold within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Chen Yajing sold about $15.5K of ZLAB on Aug 11, 2026; 1 other insider sold within 30 days and 43 funds added in the latest 13F quarter.
GAYNOR RICHARD
Director
BUY
2026-07-06 SECtraded 2026-07-01
1,736
$33.1K
+25.8%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Mar 17, 2026.
  • The trade is 2.2% of the 80,737 shares held after it.
  • No other insider bought within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GAYNOR RICHARD bought about $33.1K of ZLAB on Jul 1, 2026; 43 funds added in the latest 13F quarter.
Du Ying
Chairperson & CEO
SELL
2026-07-01 SECtraded 2026-06-30
7,026
$130.2K
+27.3%
Context
  • 94 earlier Form 4 trades (code P or S) here by this insider (94 sales), the last on Jun 26, 2026.
  • The trade is 0.6% of the 1,203,784 shares held after it.
  • 3 other insiders sold within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairperson & CEO Du Ying sold about $130.2K of ZLAB on Jun 30, 2026; 3 other insiders sold within 30 days and 43 funds added in the latest 13F quarter.
241 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 236 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$5.1M over 180 days
-$235.1K over 90 days
below 79% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
43 funds bought in last quarter
below 56% of Pharma & Biotech
Revenue
+15.0% year over year
more than 63% of Pharma & Biotech
Margin
-38.4% net margin
more than 53% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.4% of the float short (float per yahoo 2026-10-26) · 9.0 days to cover · settled 2026-09-30
more than 64% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ZLAB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-16.3%12M
-44%-29%-15%+0%2025-102025-122026-022026-042026-062026-082026-10 2026-05-15 · Du Ying sold $1.0M2026-05-14 · Du Ying sold $1.0M2026-03-06 · Du Ying sold $971.0K2026-03-05 · Du Ying sold $961.0K2026-03-09 · Du Ying sold $951.5K2026-05-18 · Du Ying sold $950.0K2026-03-04 · Du Ying sold $689.9K2026-05-13 · Du Ying sold $682.8K2026-06-26 · Du Ying sold $428.5K2026-05-13 · Du Ying sold $315.5K2026-03-05 · Edmondson Frazor Titus III sold $296.7K2025-11-21 · Edmondson Frazor Titus III sold $283.4K2026-03-04 · Du Ying sold $268.4K2026-08-12 · Lis William sold $212.7K2026-04-02 · Amado Rafael sold $202.1K2026-04-02 · Smiley Joshua L sold $196.0K2025-12-31 · Amado Rafael sold $188.0K2026-03-03 · Amado Rafael sold $173.8K2025-12-16 · Edmondson Frazor Titus III sold $148.3K2026-06-30 · Du Ying sold $130.2K2026-06-22 · Lis William sold $127.4K2026-04-02 · Du Ying sold $113.7K2026-04-02 · Chen Yajing sold $106.0K2026-04-02 · Edmondson Frazor Titus III sold $85.5K2026-06-26 · Edmondson Frazor Titus III sold $71.6K2026-05-14 · Edmondson Frazor Titus III sold $71.0K2026-04-06 · Smiley Joshua L sold $61.7K2026-04-06 · Amado Rafael sold $56.0K2026-03-13 · Amado Rafael sold $55.1K2026-04-06 · Du Ying sold $54.3K2026-06-26 · Chen Yajing sold $39.5K2026-03-13 · Smiley Joshua L sold $36.6K2026-07-01 · GAYNOR RICHARD bought $33.1K2026-03-17 · GAYNOR RICHARD bought $32.7K2026-03-13 · Chen Yajing sold $31.7K2026-04-06 · Edmondson Frazor Titus III sold $25.0K2026-03-13 · Edmondson Frazor Titus III sold $23.9K2026-03-11 · Du Ying sold $20.4K2026-04-06 · Chen Yajing sold $17.4K2026-08-11 · Chen Yajing sold $15.5K2026-08-19 · Chen Yajing sold $7.0K2025-11-03 · Chen Yajing sold $6.4K2026-08-20 · Smiley Joshua L filed to sell $2.6M2026-08-19 · Chen Yajing filed to sell $7.0K2026-08-12 · Lis William filed to sell $212.7K2026-08-11 · Chen Yajing filed to sell $15.5K2026-06-30 · Du Ying filed to sell $130.2K2026-06-26 · Chen Yajing filed to sell $39.5K2026-06-26 · Du Ying filed to sell $428.6K2026-06-26 · Edmondson Frazor Titus III filed to sell $71.6K2026-06-22 · Lis William filed to sell $127.4K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ZLAB: institutional holders (13F)

13F holdings, latest reported quarter
RTW INVESTMENTS, LP
6,574,032 sh
$124.9M
TCG Crossover Management, LLC
6,137,627 sh
$116.6M
RA CAPITAL MANAGEMENT, L.P.
5,743,533 sh
$109.1M
ADAR1 Capital Management, LLC
3,369,034 sh
$64.0M
FMR LLC
2,815,214 sh
$53.5M

Congress trades in ZLAB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ZLAB planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Smiley Joshua L
Filed 2026-08-20
$2.6M
Chen Yajing
Filed 2026-08-19
$7.0K
Lis William
Filed 2026-08-12
$212.7K
Chen Yajing
Filed 2026-08-11
$15.5K
Du Ying
Filed 2026-06-30
$130.2K

ZLAB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Tema Oncology ETF
$3.5M position · as of 2026-05-31
2.0%
Virtus Biotech Etf
$1.5M position · as of 2026-07-31
1.5%
ALPS Medical Breakthroughs ETF
$2.0M position · as of 2026-05-31
1.3%
Fidelity Disruptive Medicine ETF
$270.2K position · as of 2026-05-31
0.7%
Baron Emerging Markets Fund
$26.0M position · as of 2026-06-30
0.7%
ULTRACHINA PROFUND
$98.3K position · as of 2026-07-31
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Samantha (Ying) Du
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$10.7M
$1.9M
$3.8M
-87%
+25%
2024
$9.1M
$12.1M
$3.6M
-81%
-7%
2023
$12.0M
$7.5M
$3.9M
-80%
-6%
2022
$20.2M
$739.6K
$6.8M
-77%
-10%
2021
$15.3M
-$30.5M
$6.2M
-54%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $5.1M sold by insiders over 180 days, 43 funds added last quarter, $2.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ZLAB financials

Revenue growth
+15.0%
XBRL, annual
Net margin
-38.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$449.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-41.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$139.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.39x
current debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-0.56x
TTM operating cash flow over current debt only, 2026-06-30
Return on equity
-26.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-16.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-35.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.8B
market value at close 2026-10-26 on 2021-02-26 shares, plus current debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-6.5%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$460.2M$399.0M$266.7M$215.0M
Operating income-$229.4M-$282.1M-$366.6M-$404.4M
Net income-$175.5M-$257.1M-$334.6M-$443.3M
EPS (diluted)-0.16-0.26-0.35-0.46
Operating cash flow-$150.8M-$214.9M-$198.2M-$367.6M
Cash$679.6M$449.7M$790.2M$1.0B
SEC XBRL, fiscal years, as known on 2026-10-27

ZLAB Stock Sonar score 6/7 axes

Find similar shapesCompare

ZLAB ranks highest on risk and compliance (72nd percentile) and profitability (67th), and lowest on insider conviction (38th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
67
Inputs
  • Return on equity-26.9% · 69 pct, sector of 545
  • Return on assets-16.8% · 69 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-35.7% · 64 pct, sector of 576
Financial health
48
Inputs
  • Debt to equity0.39x · 36 pct, sector of 352
  • Cash flow to debt-0.56x · 59 pct, sector of 371
Growth
63
Inputs
  • Revenue growth, YoY+15.0% · 63 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
38
Inputs
  • Net Form 4 buying (codes P and S), 180d-$5.1M · 19 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
44
Inputs
  • Funds adding, latest quarter43 · 44 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
72
Inputs
  • Short interest, % of float+7.4% · 48 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+1.9% · 96 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ZLAB filings, in plain words

Are Zai Lab insiders buying or selling ZLAB?

In the 180 days to 2026-10-27, Zai Lab insiders were net sellers, a net $5.1M: $33.1K of purchases and $5.1M of sales reported on Form 4, by 1 buyer and 4 sellers.

Are there planned insider sales of ZLAB?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $2.8M of stock; the latest, by Smiley Joshua L, was filed 2026-08-20.

Read the full summary

In the 180 days to 2026-10-27, Zai Lab insiders were net sellers of ZLAB, a net $5.1M across purchases and sales reported on Form 4 by 1 buyer and 4 sellers. Sales outweighed purchases more than tenfold by value. 7% of the 14 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $2.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies